BAX Stock Recent News
BAX LATEST HEADLINES
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing globally, the future of gene therapy, changes at FDA, and more.
CNBC's Joe Kernen reports on the latest news.
Baxter International (BAX) came out with quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.6 per share. This compares to earnings of $0.68 per share a year ago.
Baxter misses on Q2 earnings and sales, trims full-year EPS view, and posts weaker gross margin. Shares slide nearly 9% pre-market.
Baxter International Inc. (NYSE:BAX ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Clare Trachtman - Vice President of Investor Relations David Brent Shafer - Chair & Interim CEO Heather Knight - Executive Vice President & COO Joel T. Grade - Executive VP & CFO Conference Call Participants David Harrison Roman - Goldman Sachs Group, Inc., Research Division Lawrence H.
While the top- and bottom-line numbers for Baxter (BAX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Baxter International cut its 2025 profit forecast on Thursday, while quarterly earnings missed analysts' estimates due to the lingering effect of Hurricane Helene, which damaged a key manufacturing facility and reduced demand for IV solutions.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2025. “For the second quarter of 2025, Baxter delivered performance in line with guidance while our employees across the globe continued advancing the company's life-sustaining Mission and building on its vision to redefine healthcare delivery,” said Brent Shafer, chair and interim CEO. “The company is poised to enter a new chapter with the appointmen.
Besides Wall Street's top-and-bottom-line estimates for Baxter (BAX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.